Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Diabetes drug may fight inflammation after stent procedure

NCT ID NCT07292909

Disease control Sponsor: Hotel Dieu de France Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether empagliflozin, a diabetes drug, can reduce inflammation after a heart stent procedure. 100 patients with stable coronary artery disease will take either empagliflozin or a placebo for three days before their scheduled stent placement. Researchers will measure C-reactive protein (CRP) levels before and after the procedure to see if the drug lowers the inflammatory response.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
empagliflozin
What this could lead to
If it works, this could show that empagliflozin reduces inflammation after stent placement, potentially improving recovery and outcomes for heart patients.
What could go wrong
This is a small, early-phase trial focused on a biomarker (CRP), not clinical outcomes. The anti-inflammatory effect may be modest or not translate to real-world benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Patients with stable CAD who are electively scheduled for PCI on a de novo lesion in a native coronary artery Exclusion Criteria: * • Patients who have been taking an SGLT-2 inhibitor during the last month * Patients who are receiving any anti-inflammatory medication: immunosuppressor, steroids, NSAID… * Patients who have underlying inflammatory conditions such as rheumatic arthritis, infection, active malignancy * Patients with an acute coronary syndrome within the last month * Intervention on a restenotic lesion or lesion in a saphenous vein graft * Creatinine clearance less than 30 mL/min * Patients who are treated with devices other than balloons and stents (lithotripsy, rotational atherectomy…)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cad - coronary artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder Inflammation inflammatory disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cad - coronary artery disease Inflamation PCI SGLT 2 inhibitors

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hotel Dieu de France

    RECRUITING

    Beirut, Beirut, 00000, Lebanon

More trials for these conditions

Other studies related to the condition(s) this trial covers.